DiaBridge AB
Developing breakthrough drugs targeting DNA repair for cancer and inflammation.
Översikt
- 0
- Anställda
- ≤1t SEK
- Omsättning
- 2014
- Grundat
Nyckelbeslutsfattare
Ulrika Warpman Berglund
CEO
Gustaf Eriksson
Member of the Board
Ingvar Karlsson
Member of the Board
Thomas Helleday
Member of the Board
+5 fler kontakter i Funnelfeedr
Beskrivning
Oxcia AB is a science-led Swedish biotechnology company focused on revolutionizing treatments for cancer and inflammation. The core of their innovation lies in the unique O2-DDR technology platform, which manages oxidative stress, oxidative DNA damage, and the DNA Damage Response (DDR) in cells. Thi...